 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...100101102103104105106107108109110...132133» |
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Biomarker, New trial, Circulating tumor cells, Tumor cell: Circulating Tumor Cells and Tumor DNA in HCC and NET (clinicaltrials.gov) - Nov 25, 2016
P=N/A, N=130, Recruiting, Sponsor: University of Aarhus
- ||| everolimus / Generic mfg.
Enrollment closed, Trial primary completion date: PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children (clinicaltrials.gov) - Nov 23, 2016
P2, N=65, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Mar 2017
- | Envarsus (LCP-Tacro) / Asahi Kasei
New P2 trial, Combination therapy: Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study (clinicaltrials.gov) - Nov 22, 2016
P2, N=25, Not yet recruiting, Sponsor: Chiesi Farmaceutici S.p.A.
- SNX-5422 / Esanex
Trial primary completion date: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors (clinicaltrials.gov) - Nov 22, 2016
P1, N=19, Active, not recruiting, Sponsor: Esanex Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Mar 2017 Trial primary completion date: Oct 2016 --> Feb 2017
- everolimus / Generic mfg.
Trial suspension, Trial primary completion date: CHONRAD: A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas (clinicaltrials.gov) - Nov 22, 2016
P2, N=57, Suspended, Sponsor: Centre Leon Berard
Trial primary completion date: Oct 2016 --> Feb 2017 Recruiting --> Suspended | Trial primary completion date: Aug 2016 --> Aug 2018
- Signifor (pasireotide) / Recordati
Trial primary completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 18, 2016
P1, N=13, Active, not recruiting, Sponsor: Emory University
Recruiting --> Suspended | Trial primary completion date: Aug 2016 --> Aug 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- Herceptin (trastuzumab) / Roche
Trial primary completion date, Metastases: Phase II Trial of EVEROLIMUS (clinicaltrials.gov) - Nov 18, 2016
P2, N=34, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- |||| everolimus / Generic mfg.
Trial completion, Monotherapy, Metastases: Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 17, 2016
P2, N=85, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2016 --> Nov 2017 No longer recruiting --> Completed
- | everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Metastases: A091302: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer (clinicaltrials.gov) - Nov 17, 2016
P2, N=34, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed N=56 --> 34
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Nov 17, 2016
P2, N=74, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=56 --> 34 Recruiting --> Active, not recruiting
- |||| Herceptin (trastuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: BOLERO-1: Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 16, 2016
P3, N=719, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Jun 2017
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - Nov 15, 2016
P1, N=142, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2017 --> Jun 2017 Trial primary completion date: Jul 2017 --> Jan 2018
- everolimus / Generic mfg.
Trial primary completion date: A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD (clinicaltrials.gov) - Nov 14, 2016
P2, N=30, Recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Jul 2017 --> Jan 2018 Trial primary completion date: Dec 2016 --> Mar 2017
- ||| Nulojix (belatacept) / BMS
Clinical: Regimen Optimization Study (clinicaltrials.gov) - Nov 14, 2016
P2, N=70, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> Mar 2017 N=240 --> 70
- |||||||||| everolimus / Generic mfg.
New P3 trial: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment (clinicaltrials.gov) - Nov 13, 2016
P3, N=250, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: MOST plus: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (clinicaltrials.gov) - Nov 3, 2016
P2, N=560, Recruiting, Sponsor: Centre Leon Berard
N=240 --> 70 Trial primary completion date: Feb 2020 --> Feb 2017
- ||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Trial primary completion date, Metastases: CATChEz: Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Nov 3, 2016
P2, N=74, Active, not recruiting, Sponsor: Novartis
Trial primary completion date: Feb 2020 --> Feb 2017 Trial primary completion date: Feb 2017 --> Nov 2016 | Recruiting --> Active, not recruiting
- ||| serabelisib (MLN1117) / Takeda
Metastases: MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma (clinicaltrials.gov) - Nov 3, 2016
P2, N=189, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Feb 2017 --> Nov 2016 | Recruiting --> Active, not recruiting Initiation date: Jun 2016 --> Sep 2016
- Envarsus (LCP-Tacro) / Asahi Kasei
Clinical: Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients (clinicaltrials.gov) - Nov 3, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: Medical University of South Carolina
- || everolimus / Generic mfg.
Trial primary completion date, Metastases: Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) (clinicaltrials.gov) - Oct 25, 2016
P4, N=80, Active, not recruiting, Sponsor: iOMEDICO AG
Initiation date: Jun 2016 --> Sep 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- | lapatinib / Generic mfg., everolimus / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Metastases: Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 25, 2016
P2, N=23, Completed, Sponsor: University of Kansas Medical Center
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Completed | N=45 --> 23 | Trial primary completion date: Jul 2017 --> Aug 2016
- ||| everolimus / Generic mfg.
Enrollment closed, Trial primary completion date: Novartis Everolimus Transition (clinicaltrials.gov) - Oct 19, 2016
P4, N=60, Active, not recruiting, Sponsor: Medical University of South Carolina
Recruiting --> Completed | N=45 --> 23 | Trial primary completion date: Jul 2017 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Dec 2016
- | Signifor (pasireotide) / Recordati
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Oct 19, 2016
P1, N=22, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Dec 2016 Active, not recruiting --> Completed | N=32 --> 22 | Trial primary completion date: Apr 2016 --> Sep 2014
- everolimus / Generic mfg.
Trial primary completion date: NFC-RAD001: Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas (clinicaltrials.gov) - Oct 18, 2016
P2, N=23, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed | N=32 --> 22 | Trial primary completion date: Apr 2016 --> Sep 2014 Trial primary completion date: Sep 2016 --> Dec 2016
- || Piqray (alpelisib) / Novartis
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors (clinicaltrials.gov) - Oct 18, 2016
P1, N=78, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Active, not recruiting | N=166 --> 78 | Trial primary completion date: Apr 2018 --> Aug 2017
- everolimus / Generic mfg.
Trial primary completion date: INPRES: Influence of Exceptional Patient Characteristics on Everolimus Exposure (clinicaltrials.gov) - Oct 13, 2016
P4, N=50, Recruiting, Sponsor: Radboud University
Recruiting --> Active, not recruiting | N=166 --> 78 | Trial primary completion date: Apr 2018 --> Aug 2017 Trial primary completion date: Aug 2016 --> Dec 2016
- everolimus / Generic mfg.
Trial completion, Trial primary completion date: Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) (clinicaltrials.gov) - Oct 13, 2016
P=N/A, N=75, Completed, Sponsor: Radboud University
Trial primary completion date: Aug 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Oct 13, 2016
P2, N=25, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jan 2016 Trial primary completion date: Sep 2016 --> Jun 2017
- everolimus / Generic mfg.
Trial primary completion date: Prediction of Everolimus-induced Interstitial Lung Disease (clinicaltrials.gov) - Oct 13, 2016
P=N/A, N=25, Recruiting, Sponsor: Radboud University
Trial primary completion date: Sep 2016 --> Jun 2017 Trial primary completion date: Aug 2016 --> Dec 2016
- Erleada (apalutamide) / J&J
Enrollment closed, Enrollment change, Metastases: ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate (clinicaltrials.gov) - Oct 13, 2016
P1b, N=9, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2016 --> Dec 2016 Recruiting --> Active, not recruiting | N=58 --> 9
- everolimus / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers (clinicaltrials.gov) - Oct 12, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: St. Joseph's Healthcare Hamilton
Recruiting --> Active, not recruiting | N=58 --> 9 Trial primary completion date: Dec 2015 --> Dec 2016
- || Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: TRINITI-1: Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (clinicaltrials.gov) - Oct 11, 2016
P1/2, N=51, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jan 2018 --> Jul 2018
- | everolimus / Generic mfg.
Enrollment closed, Surgery: EVEREST: S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery (clinicaltrials.gov) - Oct 6, 2016
P3, N=1545, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Jan 2018 --> Jul 2018 Recruiting --> Active, not recruiting
- |||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Combination therapy, Metastases: KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 30, 2016
P3, N=735, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Trial primary completion date: Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation. (clinicaltrials.gov) - Sep 28, 2016
P=N/A, N=24, Recruiting, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2017 --> Oct 2019
- Herceptin (trastuzumab) / Roche
Enrollment closed, Phase classification, Enrollment change, Metastases: Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis (clinicaltrials.gov) - Sep 28, 2016
P1b/2, N=9, Active, not recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Apr 2017 --> Oct 2019 Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1b/2 | N=47 --> 9
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Sep 27, 2016
P2, N=31, Not yet recruiting, Sponsor: Eisai Inc.
- everolimus / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Sep 26, 2016
P2, N=4, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1b/2 | N=47 --> 9 Recruiting --> Active, not recruiting | N=38 --> 4 | Trial primary completion date: Feb 2017 --> Sep 2017
- ||||| everolimus / Generic mfg.
Enrollment closed: Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants (clinicaltrials.gov) - Sep 23, 2016
P3, N=286, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=38 --> 4 | Trial primary completion date: Feb 2017 --> Sep 2017 Recruiting --> Active, not recruiting
- |||| Trial completion, Combination therapy: 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (clinicaltrials.gov) - Sep 23, 2016
P4, N=612, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
Combination therapy: De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study (clinicaltrials.gov) - Sep 21, 2016
P3, N=180, Not yet recruiting, Sponsor: Rennes University Hospital
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Sep 21, 2016
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Jun 2016 --> Dec 2016
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date, Metastases: An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) (clinicaltrials.gov) - Sep 21, 2016
P4, N=15, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2016 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2016
- everolimus / Generic mfg.
Trial primary completion date, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Sep 19, 2016
P3, N=253, Recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2016 Trial primary completion date: Feb 2017 --> Feb 2018
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Combination therapy, Metastases: KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 19, 2016
P3, N=735, Not yet recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Nov 2020 --> Oct 2019
- | Ibrance (palbociclib) / Pfizer
Enrollment open, Combination therapy, Metastases: Palbociclib With Everolimus + Exemestane In BC (clinicaltrials.gov) - Sep 16, 2016
P1b/2a, N=32, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Nov 2020 --> Oct 2019 Not yet recruiting --> Recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Enrollment change, Metastases: Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer (clinicaltrials.gov) - Sep 16, 2016
P1, N=23, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=34 --> 23
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Phase classification, Enrollment change, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Sep 14, 2016
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=34 --> 23 Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123
- |||| everolimus / Generic mfg.
Trial primary completion date: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Sep 12, 2016
P3, N=365, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123 Trial primary completion date: Oct 2016 --> Oct 2017
- everolimus / Generic mfg., sirolimus / Generic mfg.
Trial completion: RAPT: Rapalogues for Autism Phenotype in TSC: A Feasibility Study (clinicaltrials.gov) - Sep 8, 2016
P2, N=3, Completed, Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Trial primary completion date: Oct 2016 --> Oct 2017 Active, not recruiting --> Completed